Credit Suisse Sticks to Its Hold Rating for Aimmune Therapeutics (AIMT)

By Ryan Adsit

Credit Suisse analyst Evan Seigerman maintained a Hold rating on Aimmune Therapeutics (AIMTResearch Report) today and set a price target of $15.00. The company’s shares closed last Wednesday at $13.83, close to its 52-week low of $10.09.

According to, Seigerman is a 5-star analyst with an average return of 29.7% and a 71.7% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Satsuma Pharmaceuticals, Vertex Pharmaceuticals, and Mirati Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aimmune Therapeutics with a $37.86 average price target, a 169.3% upside from current levels. In a report issued on July 22, Stifel Nicolaus also reiterated a Hold rating on the stock with a $18.00 price target.

See today’s analyst top recommended stocks >>

Based on Aimmune Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $575K and GAAP net loss of $86.43 million. In comparison, last year the company had a GAAP net loss of $54.27 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.